Search

Your search keyword '"Matsubara, N."' showing total 913 results

Search Constraints

Start Over You searched for: Author "Matsubara, N." Remove constraint Author: "Matsubara, N."
913 results on '"Matsubara, N."'

Search Results

1. The Duel of Magnetic Interactions & Structural Instabilities: Itinerant Frustration in the Triangular Lattice Compound LiCrSe$_2$

2. Nuclear and magnetic spin structure of the antiferromagnetic triangular lattice compound LiCrTe$_2$ investigated by $\mu^+$SR as well as neutron and X-ray diffraction

3. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

4. Neutron powder diffraction study of NaMn$_2$O$_4$ and Li$_{0.92}$Mn$_2$O$_4$: New insights on spin-charge-orbital ordering

5. Magnetism and Ion Diffusion in Honeycomb Layered Oxide K$_2$Ni$_2$TeO$_6$: First Time Study by Muon Spin Rotation & Neutron Scattering

7. Genomic profiling and clinical utility of circulating tumor DNA in metastatic renal cell carcinoma: Nationwide SCRUM-Japan MONSTAR SCREEN project

9. Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) + novel hormonal therapy (NHT) combination therapy

10. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

11. CYCLONE 3: A Phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)

12. Nuclear and magnetic spin structure of the antiferromagnetic triangular lattice compound LiCrTe2 investigated by $$\mu ^+$$SR, neutron and X-ray diffraction

13. 264P Increased membrane HER3 expression in brain metastases compared to primary tumors in breast cancer

14. 1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011

15. 1423TiP CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)

16. Does antimicrobial use density at the ward level influence monthly central line-associated bloodstream infection rates?

18. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

19. Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic

20. Surgeons' fear of getting infected by COVID19: A global survey

21. Association between ward-specific antimicrobial use density and methicillin-resistant Staphylococcus aureus surveillance: a 60-month study

22. Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

23. Qualité de vie et symptômes chez les patients atteints d’un carcinome urothélial localement avancé ou métastatique précédemment traité de l’étude Ev-301 : une étude randomisée de phase 3 comparant enfortumab vedotin à la chimiothérapie

24. TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

25. 545P First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part

27. 617P Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project

28. 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma

29. 585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)

30. P108 - Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) + novel hormonal therapy (NHT) combination therapy

36. 1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2

37. 1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study

38. 1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status

39. 1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

41. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibility

42. Study of γ d → π + π − d Reaction in an Energy Region of 0.67 ≤ E γ ≤ 1.08 GeV

43. The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility

44. Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

45. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

46. Neutron powder diffraction study of NaMn$_{2}$O$_{4}$ and Li$_{0.92}$Mn$_{2}$O$_{4}$: Insights on spin-charge-orbital ordering

48. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa

Catalog

Books, media, physical & digital resources